Keywords
How to Cite
Abstract
Introduction. For cancer patients who have failed all existing treatment standards, the use of safe drugs that have demonstrated evidence of antitumor activity in preclinical studies may be acceptable. For example, the dihydroorotate dehydrogenase (DHODH) inhibitor leflunomide, used for anti-inflammatory therapy, may have some activity against KRAS-mutated neoplasms. In addition, laboratory studies and a few clinical cases have provided information on the promising potential of combining MEK inhibitors with hydroxychloroquine for carcinomas characterized by activation of RAS family genes.
Materials and Methods. We are conducting a multicenter, prospective, cohort phase II NTO-RAS trial to investigate the potential efficacy of these approaches.
Conclusion. This article describes the rationale and design of the trial.
References
Martianov A.S., Mitiushkina N.V., Ershova A.N., et al. KRAS, NRAS, BRAF, HER2 and MSI status in a large consecutive series of colorectal carcinomas. Int J Mol Sci. 2023; 24(5): 4868.-DOI: https://doi.org/10.3390/ijms24054868.
Simanshu D.K., Nissley D.V., McCormick F. RAS proteins and their regulators in human disease. Cell. 2017; 170(1): 17-33.-DOI: https://doi.org/10.1016/j.cell.2017.06.009.
Prior I.A., Hood F.E., Hartley J.L. The frequency of RAS mutations in cancer. Cancer Res. 2020; 80(14): 2969-2974.-DOI: https://doi.org/10.1158/0008-5472.CAN-19-3682.
Huang L., Guo Z., Wang F., Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021; 6(1): 386.-DOI: https://doi.org/10.1038/s41392-021-00780-4.
Negrao M.V., Spira A.I., Heist R.S., et al. Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRASG12C-mutated non-small-cell lung cancer who have untreated CNS metastases. J Clin Oncol. 2023; 41(28): 4472-4477.-DOI: https://doi.org/10.1200/JCO.23.00046.
Sacher A., LoRusso P., Patel M.R., et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med. 2023; 389(8): 710-721.-DOI: https://doi.org/10.1056/NEJMoa2303810.
Jin R., Liu B., Liu X., et al. Leflunomide suppresses the growth of LKB1-inactivated tumors in the immune-competent host and attenuates distant cancer metastasis. Mol Cancer Ther. 2021; 20(2): 274-283.-DOI: https://doi.org/10.1158/1535-7163.MCT-20-0567.
O'Donnell E.F., Kopparapu P.R., Koch D.C., et al. The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. PLoS One. 2012; 7(7): e40926.-DOI: https://doi.org/10.1371/journal.pone.0040926.
Hanson K., Robinson S.D., Al-Yousuf K., et al. The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. Oncotarget. 2017; 9(3): 3815-3829.-DOI: https://doi.org/10.18632/oncotarget.23378.
Alamri R.D., Elmeligy M.A., Albalawi G.A., et al. Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review. Int Immunopharmacol. 2021; 93: 107398.-DOI: https://doi.org/10.1016/j.intimp.2021.107398.
Cheng L., Wang H., Wang Z., et al. Leflunomide inhibits proliferation and induces apoptosis via suppressing autophagy and PI3K/Akt signaling pathway in human bladder cancer cells. Drug Des Devel Ther. 2020; 14: 1897-1908.-DOI: https://doi.org/10.2147/DDDT.S252626.
Madak J.T., Bankhead A. 3rd, Cuthbertson C.R., et al. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Pharmacol Ther. 2019; 195: 111-131.-DOI: https://doi.org/10.1016/j.pharmthera.2018.10.012.
Koundinya M., Sudhalter J., Courjaud A., et al. Dependence on the pyrimidine biosynthetic enzyme DHODH is a synthetic lethal vulnerability in mutant KRAS-driven cancers. Cell Chem Biol. 2018; 25(6): 705-717.e11.-DOI: https://doi.org/10.1016/j.chembiol.2018.03.005.
Orlov S.V., Urtenova M.A., Sviridenko M.A., et al. Rapid improvement of the performance status and reduction of the tumor size in KRAS-mutated colorectal cancer patient receiving binimetinib, hydroxychloroquine, and bevacizumab. Case Rep Oncol. 2020; 13(2): 985-989.-DOI: https://doi.org/10.1159/000509241.
Yaeger R., Corcoran R.B. Targeting alterations in the RAF-MEK pathway. Cancer Discov. 2019; 9(3): 329-341.-DOI: https://doi.org/10.1158/2159-8290.CD-18-1321.
Stalnecker C.A., Der C.J. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers. Sci Signal. 2020; 13(624): eaay6013.-DOI: https://doi.org/10.1126/scisignal.aay6013.
Bryant K.L., Stalnecker C.A., Zeitouni D., et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019; 25(4): 628-640.-DOI: https://doi.org/10.1038/s41591-019-0368-8.
Kinsey C.G., Camolotto S.A., Boespflug A.M., et al. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med. 2019; 25(4): 620-627.-DOI: https://doi.org/10.1038/s41591-019-0367-9.
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10(1): 1-10.-DOI: https://doi.org/10.1016/0197-2456(89)90015-9.
Mross K., Frost A., Steinbild S., et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012; 18(9): 2658-67.-DOI: https://doi.org/10.1158/1078-0432.CCR-11-1900.
Brahmer J.R., Drake C.G., Wollner I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19): 3167-75.-DOI: https://doi.org/10.1200/JCO.2009.26.7609.
Saint-Raymond A., Hill S., Martines J., et al. CONSORT 2010. Lancet. 2010; 376(9737): 229-30.-DOI: https://doi.org/10.1016/S0140-6736(10)61134-8.
Kaltwasser J.P., Nash P., Gladman D., et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004; 50(6): 1939-50.-DOI: https://doi.org/10.1002/art.20253.
Gonzalez-Cao M., Mayo de Las Casas C., Oramas J., et al. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nat Commun. 2021; 12(1): 7008.-DOI: https://doi.org/10.1038/s41467-021-26572-6.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2024